1. Volume 366, Issue 9484, Pages 455-462 (August 2005)
Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial 
Prof Raimund Jakesz, MD, Prof Walter Jonat, MD, Prof Michael Gnant, MD, Prof Martina Mittlboeck, PhD, Prof Richard Greil, MD, Christoph Tausch, MD, Prof Joern Hilfrich, MD, Werner Kwasny, MD, Prof Christian Menzel, MD, Prof Hellmut Samonigg, MD, Prof Michael Seifert, MD, Prof Guenther Gademann, MD, Prof Manfred Kaufmann, MD 
The Lancet 
Volume 366, Issue 9484, Pages (August 2005)
DOI: /S (05)
Copyright © 2005 Elsevier Ltd Terms and Conditions

2. Figure 1
Trial profile
The Lancet  , DOI: ( /S (05) )
Copyright © 2005 Elsevier Ltd Terms and Conditions

3. Figure 2 Kaplan-Meier curves of event-free survival
0 timepoint=2 years after surgery. SD at 3 years: tamoxifen=0·81, anastrozole=0·65
The Lancet  , DOI: ( /S (05) )
Copyright © 2005 Elsevier Ltd Terms and Conditions

4. Figure 3
HR (95%CI) for anastrozole versus tamoxifen stratified by nodal status, tumour grade, age, and hormone receptor status
ER=oestrogen receptor; PgR=progesterone receptor.
The Lancet  , DOI: ( /S (05) )
Copyright © 2005 Elsevier Ltd Terms and Conditions

5. Figure 4 Kaplan-Meier curves of distant recurrence-free survival
0 timepoint=2 years after surgery. SD at 3 years: tamoxifen=0·76, anastrozole=0·52.
The Lancet  , DOI: ( /S (05) )
Copyright © 2005 Elsevier Ltd Terms and Conditions